Aurora Cannabis
Aurora Cannabis is arguably one of the best known and most popular cannabis companies. In March 2022, Aurora Cannabis’ stock market value was around 797 million euros.
Aurora Cannabis further expanded its strong position in the cannabis industry with the acquisition of organic cannabis company Whistler in January 2019. Whistler operates indoor licensed production facilities and is one of eight companies that were the first to receive permission from Canadian authorities to grow cannabis for the legal market. With the Whistler acquisition, Aurora further diversified its own offering. The company’s focus remains on overseas expansion. For example, a large hemp production plant is planned in Denmark for the cultivation of pharmaceutical marijuana.
Aurora Cannabis offers a particularly wide range of products, including dried cannabis, softgels for pill making, cannabis oil and THC powder as an alternative to smoking or adding to food and beverages. That breadth of product lineup is one reason, among many, for Aurora Cannabis’ fantastic growth: Revenue for the popular cannabis conglomerate rose 260 percent year over year in the second fiscal quarter of 2018.
2019 was a bright year for Aurora Cannabis stock. John Chu, analyst at Laurentian Bank, suggested that Aurora could have the potential to be a leader in the medical, wellness, nutraceutical (standardized nutrient) and over-the-counter drug markets. The cannabis analyst explained this as part of his balance sheet criticism in early 2019in which he simultaneously issued a clear buy recommendation for Aurora Cannabis stock.
However, this has changed in 2022. Like Tilray, Aurora Cannabis stock is no longer among the best this year. In 2021, the maximum value of the paper was 8.69 euros. On March 15, 2022, the share price fell to EUR 2.64, reaching its lowest level in 52 weeks. According to analysts, Cannabis stocks are likely to post a loss of -C$0.588 in 2023.